Fernández-Armenteros JM, Gómez-Arbonés X, Buti-Soler M,
et al. Psoriasis, metabolic syndrome and cardiovascular risk
factors. A population-based...
Aksentijevich M, Lateef SS, Anzenberg P, Dey AK, Mehta NN.
Chronic inflammation, cardiometabolic diseases and effects
of treatment: psoriasis...
Caiazzo G, Fabbrocini G, Di Caprio R, et al. Psoriasis,
cardiovascular events, and biologics: lights and shadows.
Front Immunol. 2018;9:1668....
Shah SR, Abbasi Z, Fatima M, et al. Canakinumab and
cardiovascular outcomes: results of the CANTOS trial. J
Community Hosp Intern Med Perspect....
Paiva-Lopes MJ, Batuca JR, Gouveia S, Alves M, Papoila AL,
Alves JD. Antibodies towards high-density lipoprotein components in patients with...
Kleyn CE, Talbot PS, Mehta NN, et al. Psoriasis and mental
health workshop report: exploring the links between psychosocial factors, psoriasis,...
Egeberg A, Khalid U, Gislason GH, Mallbris L, Skov L, Hansen
PR. Impact of depression on risk of myocardial infarction,
stroke and cardiovascular...
Rungapiromnan W, Mason KJ, Lunt M, et al. Risk of major
cardiovascular events in patients with psoriasis receiving
biologic therapies: a prospective...
Crowley JJ, Warren RB, Cather JC. Safety of selective IL-23p19
inhibitors for the treatment of psoriasis. J Eur Acad Dermatol
Venereol JEADV....
Joshi AA, Lerman JB, Dey AK, et al. Association between aortic
vascular inflammation and coronary artery plaque characteristics in psoriasis....
Gonzalez-Cantero A, Gonzalez-Cantero J, Sanchez-Moya AI,
et al. Subclinical atherosclerosis in psoriasis. Usefulness of
femoral artery ultrasound...
Elnabawi YA, Dey AK, Goyal A, et al. Coronary artery plaque
characteristics and treatment with biologic therapy in severe
psoriasis: results...
Knowles L, Nadeem N, Chowienczyk PJ. Do anti-tumour
necrosis factor-α biologics affect subclinical measures of
atherosclerosis and arteriosclerosis?...
Marovt M, Marko PB, Pirnat M, Ekart R. Effect of biologics
targeting interleukin-23/-17 axis on subclinical atherosclerosis: results of a...
Villasante Fricke AC, Iacobellis G. Epicardial adipose tissue:
clinical biomarker of cardio-metabolic risk. Int J Mol Sci. 2019;
20(23). https://doi.org/10.3390/ijms20235989.
Ait-Oufella H, Libby P, Tedgui A. Anticytokine immune
therapy and atherothrombotic cardiovascular risk. Arterioscler
Thromb Vasc Biol. 2019;39(8):1510–1519....
Elnabawi YA, Teague HL, Joshi AA, et al. Association of
biologic therapy with coronary inflammation in patients with
psoriasis as assessed...
Beringer A, Miossec P. Systemic effects of IL-17 in inflammatory arthritis. Nat Rev Rheumatol. 2019;15(8):491–501. https://
doi.org/10.1038/s41584-019-0243-5.
Schüler R, Brand A, Klebow S, et al. Antagonization of IL-17A
attenuates skin inflammation and vascular dysfunction in
mouse models of psoriasis....
Ruiz de Morales JMG, Puig L, Daudén E, et al. Critical role of
interleukin (IL)-17 in inflammatory and immune disorders: an
updated review...
Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of
C-reactive protein and low-density lipoprotein cholesterol
levels in the prediction...
Németh B, Péter I, Boncz I, et al. Urinary orosomucoid: a new
marker of cardiovascular risk in psoriatic patients? Ther Clin
Risk Manag. 2019;15:831–837....
Pona A, Haidari W, Kolli SS, Feldman SR. Diet and psoriasis.
Dermatol Online J. 2019;25(2).
Komine M. Recent advances in psoriasis research; the clue to
mysterious relation to gut microbiome. Int J Mol Sci. 2020;21(7).
https://doi.org/10.3390/ijms21072582.